Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 12/20 | 0.56 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.54 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.54 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.54 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.54 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 6/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.54 |
| ▸ | GPR183 | P32249 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653016 | 0.94 | HTR2A (0.62) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| SCHEMBL31707510 | 0.80 | HTR2A (0.58) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| SCHEMBL4980231 | 0.79 | RAB9A (0.74) | HRH3NPC1RAB9ASMN1; SMN2MCHR1 | |
| SCHEMBL4975779 | 0.79 | DRD4 (0.59) | HRH3NPC1RAB9ASMN1; SMN2MCHR1 | |
| Cadaverine Tartrate SCHEMBL27703324 | 0.77 | HTR2A (0.90) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| Pimavanserin SCHEMBL19975532 | 0.77 | HTR2A (0.90) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| Pimavanserin SCHEMBL1395694 | 0.77 | HTR2A (0.90) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| Pimavanserin SCHEMBL29384707 | 0.77 | HTR2A (0.90) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| SCHEMBL31202793 | 0.77 | MAPT (0.58) | HTR2AHTR2CHRH3ABCB11CYP1A2 | |
| SCHEMBL4981939 | 0.77 | EPHX1 (0.71) | HRH3NPC1RAB9ASMN1; SMN2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732615-B2 | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | ACADIA PHARMACEUTICALS INC. | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106063-A1 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | MTAP, CPN1, DNPEP | HTR2A 2053/4885ADRB2 4377/4885CHRM2 1546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.